Company intelligence / Profile preview

LifeMine Therapeutics

Cambridge, Massachusetts, United Stateslifeminetx.com ↗

Ownership: Private
Employees: ~100
Development stage: Preclinical

Overview

First participant dosed in Phase 1 clinical trial of LIFE-001 (a novel calcineurin inhibitor) in April 2025. LIFE-001 has shown improved safety compared to legacy calcineurin inhibitors in preclinical studies, with efficacy in animal models of ulcerative colitis and Crohn's disease.

Therapeutic areas: GastroenterologyImmunologyInfectious Diseases
Modalities: Small moleculesgenetically-encoded small molecules (GEMs)
Industry: Biotech

Drug pipeline

1 asset

LIFE-001

Beyond the preview

Go deeper on LifeMine Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LifeMine Therapeutics.

Explore the full profile